EX-99.1 2 d332470dex991.htm PRESS RELEASE ISSUED APRIL 11, 2012 Press Release issued April 11, 2012

Exhibit 99.1

 

LOGO

BIOMET ANNOUNCES THIRD QUARTER OF FISCAL YEAR 2012 FINANCIAL RESULTS

WARSAW, Ind., April 11, 2012 – Biomet, Inc. announced today financial results for its third fiscal quarter ended February 29, 2012.

 

  •  

Net sales increased 5% (5% constant currency) worldwide to $709 million

 

  •  

Large joint reconstructive sales increased 5% (5% constant currency) worldwide and increased 6% in the U.S.

 

  •  

Sports medicine sales increased 22% (22% constant currency) worldwide, with 18% U.S. growth

 

  •  

Extremity sales grew 18% (18% constant currency) worldwide, with a 21% increase in the U.S.

 

  •  

Operating cash flow of $158 million

 

  •  

Binding offer to acquire DePuy trauma business for $280 million

Third Quarter Financial Results

Net sales increased 5% during the third quarter of fiscal year 2012 to $708.9 million, compared to net sales of $678.0 million during the third quarter of fiscal year 2011. Compared to the prior year period, changes in foreign currency exchange rates had a negligible effect on consolidated sales growth rates. U.S. net sales increased 5% to $432.8 million during the third quarter, while Europe net sales increased 2% (4% constant currency) to $176.7 million and International (primarily Canada, South America, Mexico and the Pacific Rim) net sales increased 7% (6% constant currency) to $99.4 million.

Special items (pre-tax) for the third quarter totaled $108.0 million, including $82.1 million of non-cash amortization and depreciation expense related to the Merger and $25.9 million of non-Merger related special items.

Reported operating income during the third quarter of fiscal year 2012 was $108.1 million, compared to operating income of $94.9 million during the third quarter of fiscal year 2011. Adjusted operating income totaled $216.1 million during the third fiscal quarter, compared to adjusted operating income of $212.8 million in the same period of the prior fiscal year.

Reported net loss during the third quarter of fiscal year 2012 was $16.5 million, compared to a net loss of $11.6 million during the third quarter of fiscal year 2011. Adjusted net income was $55.1 million during the third fiscal quarter, compared to $63.8 million during the third quarter of fiscal year 2011.

Adjusted earnings before interest, taxes, depreciation and amortization (“EBITDA”) was $260.5 million, or 36.7% of net sales during the third quarter of fiscal year 2012, compared to adjusted EBITDA of $258.4 million during the third quarter of the prior fiscal year.

Interest expense during the third quarter totaled $117.2 million, compared to $124.0 million during the third quarter of fiscal year 2011, principally due to lower average interest rates on our term loans.

Reported cash flow from operations during the third quarter totaled $157.5 million, compared to $151.8 million for the third quarter of fiscal year 2011. Free cash flow (operating cash flow of $157.5 million minus capital expenditures of $41.5 million) was $116.0 million, which reflected $47.3 million of cash interest paid in the quarter. Free cash flow during the same quarter of fiscal year 2011 was $106.7 million.

Reported gross debt was $5.920 billion, and cash and cash equivalents, as defined in the Company’s credit agreement dated September 25, 2007, totaled $496.0 million, resulting in net debt of $5.424 billion as of February 29, 2012. From May 31, 2008, the first fiscal year-end after the Merger, to February 29, 2012, net debt decreased by $749.1 million due to an increase in cash and cash equivalents, as defined by our credit agreement, of $368.4 million and a $380.7 million reduction of gross debt. The reduction of gross debt includes a $179.4 million decrease due to favorable foreign currency translation on the Company’s euro-denominated debt.

The Company’s senior secured leverage ratio as of February 29, 2012 was 2.83 times the last twelve months (“LTM”) adjusted EBITDA, as defined by our credit agreement, compared to 4.01 times at May 31, 2008. The total leverage ratio was 5.35 times LTM adjusted EBITDA at February 29, 2012, compared to 6.97 times as of May 31, 2008.

Biomet’s President and Chief Executive Officer Jeffrey R. Binder commented, “We reported strong and improving sales results across many of our product categories this quarter, with particularly good momentum in our Large Joint Reconstructive and S.E.T. product categories. I was particularly happy with the consistency of our performance across all geographies. In addition, we are very excited about our future opportunities in the trauma market given our pending acquisition of DePuy’s worldwide trauma business.”

The following table provides third quarter net sales performance by product category:

 

     Third Quarter Net Sales Performance  
     Worldwide      Worldwide     Worldwide     United  
     Reported      Reported     CC     States  
     Quarter 3 - FY 2012      Growth %     Growth %     Growth %  

Large Joint Reconstructive

    $  422.7         5 %      5 %      6 % 

Knees

         4 %      4 %      4 % 

Hips

         6 %      6 %      7 % 

Bone Cement and Other

         6 %      7 %      8 % 

Sports, Extremities, Trauma (S.E.T.)

      92.7         16 %      16 %      15 % 

Sports Medicine

         22 %      22 %      18 % 

Extremities

         18 %      18 %      21 % 

Trauma

         1 %      1 %      (6 )% 

Spine & Bone Healing

      76.5         (5 )%      (5 )%      (5 )% 

Spine

         (3 )%      (3 )%      (3 )% 

Bone Healing

         (10 )%      (10 )%      (10 )% 

Dental

      65.6         (2 )%      (2 )%      12 % 

Other

      51.4         8 %      9 %      —   % 
  

 

 

     

 

 

    

 

 

    

 

 

  

Net Sales

    $ 708.9         5 %      5 %      5 % 
  

 

 

     

 

 

    

 

 

    

 

 

  

Large Joint Reconstructive sales grew 5% (5% constant currency) worldwide to $422.7 million and increased 6% in the U.S. during the third quarter of fiscal year 2012 compared to the third quarter of fiscal year 2011. Knee sales increased 4% (4% constant currency) worldwide and in the U.S. during the third quarter. Hip sales increased 6% (6% at constant currency) worldwide during the third quarter and grew 7% in the U.S.

Sports, Extremities and Trauma (S.E.T.) sales increased 16% (16% constant currency) worldwide to $92.7 million during the third quarter and increased 15% in the U.S. Sports medicine sales grew 22% worldwide and on a constant currency basis and increased 18% in the U.S. Extremity sales increased 18% (18% constant currency) worldwide during the quarter, with U.S. growth of 21%. Trauma sales increased 1% (1% constant currency) worldwide during the quarter and decreased 6% in the U.S.

During the third quarter, Spine and Bone Healing (non-invasive trauma stimulation and bracing) sales decreased 5% (5% constant currency) worldwide to $76.5 million, and decreased 5% in the U.S.

Worldwide Dental sales decreased 2% (2% constant currency) to $65.6 million and increased 12% in the U.S. during the third quarter.

Sales of Other products increased 8% (9% constant currency) worldwide to $51.4 million, and were flat in the U.S. during the quarter.

About Biomet

Biomet, Inc. and its subsidiaries design, manufacture and market products used primarily by musculoskeletal medical specialists in both surgical and non-surgical therapy. Biomet’s product portfolio encompasses large joint reconstructive products, including orthopedic joint replacement devices, and bone cements and accessories; sports medicine, extremities and trauma products, including internal and external orthopedic fixation devices; spine and bone healing products, including spine hardware, spinal stimulation devices, and orthobiologics, as well as electrical bone growth stimulators and softgoods and bracing; dental reconstructive products; and other products, including microfixation products and autologous therapies. Headquartered in Warsaw, Indiana, Biomet and its subsidiaries currently distribute products in approximately 90 countries.

Contacts

For further information contact Daniel P. Florin, Senior Vice President and Chief Financial Officer, at (574) 372-1687 or Barbara Goslee, Director, Corporate Communications at (574) 372-1514.

Financial Schedule Presentation

The Company’s unaudited condensed consolidated financial statements as of and for the three months and nine months ended February 29, 2012 and February 28, 2011 and other financial data included in this press release have been prepared in a manner that complies, in all material respects, with generally accepted accounting principles (“GAAP”) in the United States (except with respect to certain non-GAAP financial measures discussed below) and reflects purchase accounting adjustments related to the Merger referenced below.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. Those statements are often indicated by the use of words such as “will,” “intend,” “anticipate,” “estimate,” “expect,” “plan” and similar expressions. Forward-looking statements involve certain risks and uncertainties. Actual results may differ materially from those contemplated by the forward looking statements due to, among others, the following factors: the success of the Company’s principal product lines; the results of the ongoing investigation by the United States Department of Justice; the ability to successfully implement new technologies; the Company’s ability to sustain sales and earnings growth; the Company’s success in achieving timely approval or clearance of its products with domestic and foreign regulatory entities; the impact to the business as a result of compliance with federal, state and foreign governmental regulations and with the Deferred Prosecution Agreement and Corporate Integrity Agreement; the impact to the business as a result of the economic downturn in both foreign and domestic markets; the impact of federal health care reform; the impact of anticipated changes in the musculoskeletal industry and the ability of the Company to react to and capitalize on those changes; the ability of the Company to successfully implement its desired organizational changes and cost-saving initiatives; the impact to the business as a result of the Company’s significant international operations, including, among others, with respect to foreign currency fluctuations and the success of the Company’s transition of certain manufacturing operations to China; the impact of the Company’s managerial changes; the ability of the Company’s customers to receive adequate levels of reimbursement from third-party payors; the Company’s ability to maintain its existing intellectual property rights and obtain future intellectual property rights; the impact to the business as a result of cost containment efforts of group purchasing organizations; the Company’s ability to retain existing independent sales agents for its products; and other factors set forth in the Company’s filings with the SEC, including the Company’s most recent annual report on Form 10-K and quarterly reports on Form 10-Q. Although the Company believes that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or non-occurrence of future events. There can be no assurance as to the accuracy of forward-looking statements contained in this press release. The inclusion of a forward-looking statement herein should not be regarded as a representation by the Company that the Company’s objectives will be achieved. The Company undertakes no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements which speak only as of the date on which they were made.

*Non-GAAP Financial Measures:

Management uses non-GAAP financial measures, such as net sales excluding the impact of foreign currency (constant currency), operating income as adjusted, Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) as adjusted, net income as adjusted, gross profit as adjusted, selling, general and administrative expense as adjusted, research and development expense as adjusted, cash and cash equivalents (as defined by our credit agreement), net debt, senior secured leverage ratio, total leverage ratio (net debt), free cash flow, and unlevered free cash flow. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP measures are included elsewhere in the press release.

The term “as adjusted,” a non-GAAP financial measure, refers to financial performance measures that exclude certain income statement line items, such as interest, taxes, depreciation or amortization, other (income) expense, and/or exclude certain expenses as defined by our credit agreement, such as restructuring charges, non-cash impairment charges, integration and facilities opening costs or other business optimization expenses, new systems design and implementation costs, certain start-up costs and costs related to consolidation of facilities, certain non-cash charges, advisory fees paid to the Company’s private equity owners, certain severance charges, purchase accounting costs, stock-based compensation, litigation costs, and other related charges.

These non-GAAP financial measures are not in accordance with, or an alternative for, GAAP in the United States. Biomet management believes that these non-GAAP financial measures provide useful information to investors; however, this additional non-GAAP financial information is not meant to be considered in isolation or as a substitute for financial information prepared in accordance with GAAP.

Non-GAAP Reconciliation

A reconciliation of reported results to adjusted results is included in this press release, which is also posted on Biomet’s website: www.biomet.com

Reclassifications

Certain prior period amounts have been reclassified to conform to the current presentation. Such reclassifications were limited to net sales information by product and geographic categories. The current presentation aligns with how the Company presently reports sales and markets its products.

The Merger

Biomet, Inc. finalized the merger with LVB Acquisition Merger Sub, Inc., a wholly-owned subsidiary of LVB Acquisition, Inc., which we refer to in this press release as the “Merger”, on September 25, 2007. LVB Acquisition, Inc. is indirectly owned by investment partnerships directly or indirectly advised or managed by The Blackstone Group, Goldman Sachs & Co., Kohlberg Kravis Roberts & Co. and TPG Capital.

Biomet, Inc.

Product Net Sales

Three Month Period Ended February 29, 2012 and February 28, 2011

(in millions, except percentages, unaudited)

 

     Three Months Ended
February 29, 2012		      Three Months Ended
February 28, 2011		      Reported
Growth %		     Constant
Currency*
Growth %		  

Large Joint Reconstructive

    $ 422.7       $ 402.6         5  %      5  % 

Sports, Extremities, Trauma (S.E.T.)

      92.7         80.2         16  %      16  % 

Spine & Bone Healing

      76.5         80.6         (5 )%      (5 )% 

Dental

      65.6         67.2         (2 )%      (2 )% 

Other

      51.4         47.4         8  %      9  % 
  

 

 

     

 

 

     

 

 

    

 

 

  

Net Sales

    $ 708.9       $ 678.0         5  %      5  % 
  

 

 

     

 

 

     

 

 

    

 

 

  

 

     Three Months Ended
February 29, 2012
Net Sales Growth
As Reported		     Currency
Impact*		     Three Months Ended
February 29, 2012
Net Sales Growth in
Local Currencies*		  

Large Joint Reconstructive

      5  %      —   %      5  % 

Knees

      4 %      —   %      4 % 

Hips

      6 %      —   %      6 % 

Bone Cement and Other

      6 %      1 %      7 % 

Sports, Extremities, Trauma (S.E.T.)

      16 %      —   %      16 % 

Sports Medicine

      22 %      —   %      22 % 

Extremities

      18 %      —   %      18 % 

Trauma

      1 %      —   %      1 % 

Spine & Bone Healing

      (5 )%      —   %      (5 )% 

Spine

      (3 )%      —   %      (3 )% 

Bone Healing

      (10 )%      —   %      (10 )% 

Dental

      (2 )%      —   %      (2 )% 

Other

      8 %      1 %      9 % 
  

 

 

    

 

 

    

 

 

  

Net Sales

      5 %      —   %      5 % 
  

 

 

    

 

 

    

 

 

  

 

* See Non-GAAP Financial Measures Disclosure

Biomet, Inc.

Product Net Sales

Nine Month Period Ended February 29, 2012 and February 28, 2011

(in millions, except percentages, unaudited)

 

     Nine Months Ended
February 29, 2012		      Nine Months Ended
February 28, 2011		      Reported
Growth %		     Constant
Currency*
Growth %		  

Large Joint Reconstructive

    $ 1,259.2       $ 1,205.1         4  %      3  % 

Sports, Extremities, Trauma (S.E.T.)

      258.2         228.0         13  %      12  % 

Spine & Bone Healing

      230.1         247.2         (7 )%      (7 )% 

Dental

      198.5         195.5         2  %      —   % 

Other

      152.6         141.2         8  %      7  % 
  

 

 

     

 

 

     

 

 

    

 

 

  

Net Sales

    $ 2,098.6       $ 2,017.0         4  %      3  % 
  

 

 

     

 

 

     

 

 

    

 

 

  

 

     Nine Months Ended
February 29, 2012
Net Sales Growth
As Reported		     Currency
Impact*		     Nine Months Ended
February 29, 2012
Net Sales Growth in
Local Currencies*		  

Large Joint Reconstructive

      4  %      (1 ) %      3  % 

Knees

      3 %      (2 )%      1 % 

Hips

      7 %      (2 )%      5 % 

Bone Cement and Other

      6 %      (2 )%      4 % 

Sports, Extremities, Trauma (S.E.T.)

      13 %      (1 )%      12 % 

Sports Medicine

      18 %      (1 )%      17 % 

Extremities

      17 %      (1 )%      16 % 

Trauma

      (1 )%      (1 )%      (2 )% 

Spine & Bone Healing

      (7 )%      —   %      (7 )% 

Spine

      (6 )%      (1 )%      (7 )% 

Bone Healing

      (8 )%      —   %      (8 )% 

Dental

      2 %      (2 )%      —   % 

Other

      8 %      (1 )%      7 % 
  

 

 

    

 

 

    

 

 

  

Net Sales

      4 %      (1 )%      3 % 
  

 

 

    

 

 

    

 

 

  

 

* See Non-GAAP Financial Measures Disclosure

Biomet, Inc.

Geographic Net Sales

Three Month Period Ended February 29, 2012 and February 28, 2011

(in millions, except percentages, unaudited)

 

     Three Months Ended
February 29, 2012		      Three Months Ended
February 28, 2011		      Reported
Growth %		     Constant
Currency*
Growth %		  

Geographic Sales:

           

United States

    $ 432.8       $ 412.3         5 %      5 % 

Europe

      176.7         173.0         2 %      4 % 

International

      99.4         92.7         7 %      6 % 
  

 

 

     

 

 

     

 

 

    

 

 

  

Net Sales

    $ 708.9       $ 678.0         5 %      5 % 
  

 

 

     

 

 

     

 

 

    

 

 

  

 

     Three Months Ended           Three Months Ended  
     February 29, 2012           February 29, 2012  
     Net Sales Growth     Currency     Net Sales Growth  
     As Reported     Impact*     Local Currencies*  

United States

      5 %      —   %      5 % 

Europe

      2 %      2 %      4 % 

International

      7 %      (1 )%      6 % 
  

 

 

    

 

 

    

 

 

  

Total

      5 %      —   %      5 % 
  

 

 

    

 

 

    

 

 

  

 

* See Non-GAAP Financial Measures Disclosure

Biomet, Inc.

Geographic Net Sales

Nine Month Period Ended February 29, 2012 and February 28, 2011

(in millions, except percentages, unaudited)

 

     Nine Months Ended
February 29, 2012		      Nine Months Ended
February 28, 2011		      Reported
Growth %		     Constant
Currency*
Growth %		  

Geographic Sales:

           

United States

    $ 1,273.8       $ 1,247.6         2 %      2 % 

Europe

      520.3         499.0         4 %      1 % 

International

      304.5         270.4         13 %      7 % 
  

 

 

     

 

 

     

 

 

    

 

 

  

Net Sales

    $ 2,098.6       $ 2,017.0         4 %      3 % 
  

 

 

     

 

 

     

 

 

    

 

 

  

 

     Nine Months Ended
February 29, 2012
Net Sales Growth
As Reported		     Currency
Impact*		     Nine Months Ended
February 29, 2012
Net Sales Growth
Local Currencies*		  

United States

      2 %      —   %      2 % 

Europe

      4 %      (3 )%      1 % 

International

      13 %      (6 )%      7 % 
  

 

 

    

 

 

    

 

 

  

Total

      4 %      (1 )%      3 % 
  

 

 

    

 

 

    

 

 

  

 

* See Non-GAAP Financial Measures Disclosure

Biomet, Inc.

As Reported Consolidated Statements of Operations

(in millions, except percentages, unaudited)

 

     Three Months Ended
February 29, 2012		     Three Months Ended
February 28, 2011		  

Net sales

    $ 708.9      $ 678.0   

Cost of sales

      219.7        208.1   
  

 

 

    

 

 

  

Gross profit

      489.2        469.9   

Gross profit percentage

      69.0 %      69.3 % 

Selling, general and administrative expense

      268.4        252.9   

Research and development expense

      30.1        28.8   

Amortization

      82.6        93.3   
  

 

 

    

 

 

  

Operating income

      108.1        94.9   

Percentage of Net Sales

      15.2 %      14.0 % 

Interest expense

      117.2        124.0   

Other (income) expense

      (2.8 )      (3.0 ) 
  

 

 

    

 

 

  

Loss before income taxes

      (6.3 )      (26.1 ) 

Provision (benefit) from income taxes

      10.2        (14.5 ) 
  

 

 

    

 

 

  

Tax rate

      -161.9 %      55.6 % 

Net loss

    $ (16.5 )    $ (11.6 ) 
  

 

 

    

 

 

  

Percentage of Net Sales

      -2.3 %      -1.7 % 

Biomet, Inc.

As Reported Consolidated Statements of Operations

(in millions, except percentages, unaudited)

 

     Nine Months Ended
February 29, 2012		     Nine Months Ended
February 28, 2011		  

Net sales

    $ 2,098.6      $ 2,017.0   

Cost of sales

      669.9        609.6   
  

 

 

    

 

 

  

Gross profit

      1,428.7        1,407.4   

Gross profit percentage

      68.1 %      69.8 % 

Selling, general and administrative expense

      800.9        765.4   

Research and development expense

      93.2        88.3   

Amortization

      250.0        283.3   
  

 

 

    

 

 

  

Operating income

      284.6        270.4   

Percentage of Net Sales

      13.6 %      13.4 % 

Interest expense

      363.4        373.7   

Other (income) expense

      9.3        (8.7 ) 
  

 

 

    

 

 

  

Loss before income taxes

      (88.1 )      (94.6 ) 

Benefit from income taxes

      (18.4 )      (57.6 ) 
  

 

 

    

 

 

  

Tax rate

      20.9 %      60.9 % 

Net loss

    $ (69.7 )    $ (37.0 ) 
  

 

 

    

 

 

  

Percentage of Net Sales

      -3.3 %      -1.8 % 

Biomet, Inc.

Other Financial Information

Reconciliation of Operating Income, as reported to Operating Income, as adjusted*

(in millions, unaudited)

 

     Three Months Ended
February 29, 2012		      Three Months Ended
February 28, 2011		  

Operating income, as reported

    $ 108.1       $ 94.9   

Purchase accounting depreciation

      1.6         4.5   

Purchase accounting amortization

      80.5         91.2   
  

 

 

     

 

 

  

Total merger related depreciation and amortization

      82.1         95.7   
  

 

 

     

 

 

  

Stock-based compensation expense

      3.5         5.2   

Litigation settlements and reserves and other legal fees

      12.8         2.3   

Operational restructuring and consulting expenses related to operational initiatives (severance, building impairments, abnormal manufacturing variances and other related costs)

      6.9         12.0   

Sponsor fee

      2.7         2.7   
  

 

 

     

 

 

  

Total non-merger related items

      25.9         22.2   
  

 

 

     

 

 

  

Total items (pre-tax) excluded per our credit agreement

      108.0         117.9   
  

 

 

     

 

 

  

Operating income, as adjusted*

    $ 216.1       $ 212.8   
  

 

 

     

 

 

  

 

* See Non-GAAP Financial Measures Disclosure

Biomet, Inc.

Other Financial Information

Reconciliation of Operating Income, as reported to Operating Income, as adjusted*

(in millions, unaudited)

 

     Nine Months Ended
February 29, 2012		      Nine Months Ended
February 28, 2011		  

Operating income, as reported

    $ 284.6       $ 270.4   

Purchase accounting depreciation

      10.7         13.3   

Purchase accounting amortization

      242.0         276.1   
  

 

 

     

 

 

  

Total merger related depreciation and amortization

      252.7         289.4   
  

 

 

     

 

 

  

Stock-based compensation expense

      12.2         14.6   

Litigation settlements and reserves and other legal fees

      21.3         9.7   

Operational restructuring and consulting expenses related to operational initiatives (severance, building impairments, abnormal manufacturing variances and other related costs)

      39.8         29.7   

Sponsor fee

      7.5         7.6   
  

 

 

     

 

 

  

Total non-merger related items

      80.8         61.6   
  

 

 

     

 

 

  

Total items (pre-tax) excluded per our credit agreement

      333.5         351.0   
  

 

 

     

 

 

  

Operating income, as adjusted*

    $ 618.1       $ 621.4   
  

 

 

     

 

 

  

 

* See Non-GAAP Financial Measures Disclosure

Biomet, Inc.

Other Financial Information

Reconciliation of Net Loss, as reported to EBITDA, as adjusted*

(in millions, except percentages, unaudited)

 

     Three Months Ended
February 29, 2012		     Three Months Ended
February 28, 2011		  

Net loss, as reported

    $ (16.5 )    $ (11.6 ) 

Depreciation

      43.9        48.0   

Amortization

      82.6        93.3   

Interest expense

      117.2        124.0   

Other (income) expense

      (2.8 )      (3.0 ) 

Income tax provision (benefit)

      10.2        (14.5 ) 

Stock-based compensation expense

      3.5        5.2   

Litigation settlements and reserves and other legal fees

      12.8        2.3   

Operational restructuring and consulting expenses related to operational initiatives (severance, building impairments, abnormal manufacturing variances and other related costs)

      6.9        12.0   

Sponsor fee

      2.7        2.7   
  

 

 

    

 

 

  

EBITDA, as adjusted*

    $ 260.5      $ 258.4   
  

 

 

    

 

 

  

Net sales

    $ 708.9      $ 678.0   

EBITDA percentage, as adjusted*

      36.7  %      38.1  % 

 

* See Non-GAAP Financial Measures Disclosure

Biomet, Inc.

Other Financial Information

Reconciliation of Net Loss, as reported to EBITDA, as adjusted*

(in millions, except percentages, unaudited)

 

     Nine Months Ended
February 29, 2012		     Nine Months Ended
February 28, 2011		  

Net loss, as reported

    $ (69.7 )    $ (37.0 ) 

Depreciation

      138.0        134.2   

Amortization

      250.0        283.3   

Interest expense

      363.4        373.7   

Other (income) expense

      9.3        (8.7 ) 

Income tax benefit

      (18.4 )      (57.6 ) 

Stock-based compensation expense

      12.2        14.6   

Litigation settlements and reserves and other legal fees

      21.3        9.7   

Operational restructuring and consulting expenses related to operational initiatives (severance, building impairments, abnormal manufacturing variances and other related costs)

      39.8        29.7   

Sponsor fee

      7.5        7.6   
  

 

 

    

 

 

  

EBITDA, as adjusted*

    $ 753.4      $ 749.5   
  

 

 

    

 

 

  

Net sales

    $ 2,098.6      $ 2,017.0   

EBITDA percentage, as adjusted*

      35.9 %      37.2 % 

 

* See Non-GAAP Financial Measures Disclosure

Biomet, Inc.

Other Financial Information

Reconciliation of Net Loss, as reported to Net Income, as adjusted*

(in millions, unaudited)

 

     Three Months Ended
February 29, 2012		     Three Months Ended
February 28, 2011		  

Net loss, as reported

    $ (16.5 )    $ (11.6 ) 

Purchase accounting depreciation

      1.6        4.5   

Purchase accounting amortization

      80.5        91.2   

Stock-based compensation expense

      3.5        5.2   

Litigation settlements and reserves and other legal fees

      12.8        2.3   

Operational restructuring and consulting expenses related to operational initiatives (severance, building impairments, abnormal manufacturing variances and other related costs)

      6.9        12.0   

Sponsor fee

      2.7        2.7   

Tax effect on special and purchase accounting items**

      (36.4 )      (42.5 ) 
  

 

 

    

 

 

  

Net income, as adjusted*

    $ 55.1      $ 63.8   
  

 

 

    

 

 

  

 

* See Non-GAAP Financial Measures Disclosure
** The tax effect is calculated based upon the statutory rates for the jurisdictions where the items were incurred

Biomet, Inc.

Other Financial Information

Reconciliation of Net Loss, as reported to Net Income, as adjusted*

(in millions, unaudited)

 

     Nine Months Ended
February 29, 2012		     Nine Months Ended
February 28, 2011		  

Net loss, as reported

    $ (69.7 )    $ (37.0 ) 

Purchase accounting depreciation

      10.7        13.3   

Purchase accounting amortization

      242.0        276.1   

Stock-based compensation expense

      12.2        14.6   

Litigation settlements and reserves and other legal fees

      21.3        9.7   

Operational restructuring and consulting expenses related to operational initiatives (severance, building impairments, abnormal manufacturing variances and other related costs)

      39.8        29.7   

Sponsor fee

      7.5        7.6   

Tax effect on special and purchase accounting items**

      (117.1 )      (133.4 ) 
  

 

 

    

 

 

  

Net income, as adjusted*

    $ 146.7      $ 180.6   
  

 

 

    

 

 

  

 

* See Non-GAAP Financial Measures Disclosure
** The tax effect is calculated based upon the statutory rates for the jurisdictions where the items were incurred

Biomet, Inc.

Other Financial Information

Reconciliation of Gross Profit, as reported to Gross Profit, as adjusted*

(in millions, except percentages, unaudited)

 

     Three Months Ended
February 29, 2012		     Three Months Ended
February 28, 2011		  

Gross profit, as reported

    $ 489.2      $ 469.9   

Purchase accounting depreciation

      1.6        4.5   

Litigation settlements and reserves and other legal fees

      2.1        0.2   

Stock-based compensation expense

      0.2        0.3   

Operational restructuring and consulting expenses related to operational initiatives (severance, building impairments, abnormal manufacturing variances and other related costs)

      6.3        7.1   
  

 

 

    

 

 

  

Gross profit, as adjusted*

    $ 499.4      $ 482.0   
  

 

 

    

 

 

  

Net sales

    $ 708.9      $ 678.0   

Gross profit percentage, as reported

      69.0 %      69.3 % 

Gross profit percentage, as adjusted*

      70.4 %      71.1 % 

 

* See Non-GAAP Financial Measures Disclosure

Biomet, Inc.

Other Financial Information

Reconciliation of Gross Profit, as reported to Gross Profit, as adjusted*

(in millions, except percentages, unaudited)

 

     Nine Months Ended
February 29, 2012		     Nine Months Ended
February 28, 2011		  

Gross profit, as reported

    $ 1,428.7      $ 1,407.4   

Purchase accounting depreciation

      10.7        13.3   

Litigation settlements and reserves and other legal fees

      2.0        0.2   

Stock-based compensation expense

      0.7        0.9   

Operational restructuring and consulting expenses related to operational initiatives (severance, building impairments, abnormal manufacturing variances and other related costs)

      28.8        19.6   
  

 

 

    

 

 

  

Gross profit, as adjusted*

    $ 1,470.9      $ 1,441.4   
  

 

 

    

 

 

  

Net sales

    $ 2,098.6      $ 2,017.0   

Gross profit percentage, as reported

      68.1 %      69.8 % 

Gross profit percentage, as adjusted*

      70.1 %      71.5 % 

 

* See Non-GAAP Financial Measures Disclosure

Biomet, Inc.

Other Financial Information

Reconciliation of Selling, General and Administrative Expense, as reported to Selling, General and Administrative Expense, as adjusted*

(in millions, except percentages, unaudited)

 

     Three Months Ended
February 29, 2012		     Three Months Ended
February 28, 2011		  

Selling, general and administrative expense, as reported

    $ 268.4      $ 252.9   

Stock-based compensation expense

      (2.8 )      (4.4 ) 

Litigation settlements and reserves and other legal fees

      (10.7 )      (2.1 ) 

Operational restructuring and consulting expenses related to operational initiatives (severance, building impairments, and other related costs)

      (0.6 )      (4.4 ) 

Sponsor fee

      (2.7 )      (2.7 ) 
  

 

 

    

 

 

  

Selling, general and administrative expense, as adjusted*

    $ 251.6      $ 239.3   
  

 

 

    

 

 

  

Net sales

    $ 708.9      $ 678.0   

SG&A as a percentage of net sales, as reported

      37.9 %      37.3 % 

SG&A as a percentage of net sales, as adjusted*

      35.5 %      35.3 % 

 

* See Non-GAAP Financial Measures Disclosure

Biomet, Inc.

Other Financial Information

Reconciliation of Selling, General and Administrative Expense, as reported to Selling, General and Administrative Expense, as adjusted*

(in millions, except percentages, unaudited)

 

     Nine Months Ended
February 29, 2012		     Nine Months Ended
February 28, 2011		  

Selling, general and administrative expense, as reported

    $ 800.9      $ 765.4   

Stock-based compensation expense

      (10.1 )      (12.2 ) 

Litigation settlements and reserves and other legal fees

      (19.3 )      (9.5 ) 

Operational restructuring and consulting expenses related to operational initiatives (severance, building impairments, and other related costs)

      (10.8 )      (8.7 ) 

Sponsor fee

      (7.5 )      (7.6 ) 
  

 

 

    

 

 

  

Selling, general and administrative expense, as adjusted*

    $ 753.2      $ 727.4   
  

 

 

    

 

 

  

Net sales

    $ 2,098.6      $ 2,017.0   

SG&A as a percentage of net sales, as reported

      38.2 %      37.9 % 

SG&A as a percentage of net sales, as adjusted*

      35.9 %      36.1 % 

 

* See Non-GAAP Financial Measures Disclosure

Biomet, Inc.

Other Financial Information

Reconciliation of Research and Development Expense, as reported to Research and Development Expense, as adjusted*

(in millions, except percentages, unaudited)

 

     Three Months Ended
February 29, 2012		     Three Months Ended
February 28, 2011		  

Research and development expense, as reported

    $ 30.1      $ 28.8   

Stock-based compensation expense

      (0.5 )      (0.5 ) 

Operational restructuring and consulting expenses related to operational initiatives (severance, and other related costs)

      —          (0.5 ) 
  

 

 

    

 

 

  

Research and development expense, as adjusted*

    $ 29.6      $ 27.8   
  

 

 

    

 

 

  

Net sales

    $ 708.9      $ 678.0   

R&D as a percentage of net sales, as reported

      4.2 %      4.2 % 

R&D as a percentage of net sales, as adjusted*

      4.2 %      4.1 % 

 

* See Non-GAAP Financial Measures Disclosure

Biomet, Inc.

Other Financial Information

Reconciliation of Research and Development Expense, as reported to Research and Development Expense, as adjusted*

(in millions, except percentages, unaudited)

 

     Nine Months Ended
February 29, 2012		     Nine Months Ended
February 28, 2011		  

Research and development expense, as reported

    $ 93.2      $ 88.3   

Stock-based compensation expense

      (1.4 )      (1.5 ) 

Operational restructuring and consulting expenses related to operational initiatives (severance, and other related costs)

      (0.2 )      (1.4 ) 
  

 

 

    

 

 

  

Research and development expense, as adjusted*

    $ 91.6      $ 85.4   
  

 

 

    

 

 

  

Net sales

    $ 2,098.6      $ 2,017.0   

R&D as a percentage of net sales, as reported

      4.4 %      4.4 % 

R&D as a percentage of net sales, as adjusted*

      4.4 %      4.2 % 

 

* See Non-GAAP Financial Measures Disclosure

Biomet, Inc.

Condensed Consolidated Balance Sheets

(in millions, unaudited)

 

     (Preliminary)
February 29, 2012		      May 31, 2011  

Assets

      

Cash and cash equivalents

    $ 496.0       $ 327.8   

Accounts receivable, net

      507.4         480.1   

Income tax receivable

      3.1         5.4   

Short-term investments

      3.8         41.4   

Inventories

      555.8         582.5   

Current deferred income taxes

      72.3         71.5   

Prepaid expenses and other

      111.4         109.7   

Property, plant and equipment, net

      598.9         638.4   

Intangible assets, net

      4,275.0         4,534.4   

Goodwill

      4,445.4         4,470.1   

Other assets

      69.5         95.7   
  

 

 

     

 

 

  

Total Assets

    $ 11,138.6       $ 11,357.0   
  

 

 

     

 

 

  

Liabilities and Shareholder's Equity

      

Current liabilities, excluding debt

    $ 530.2       $ 502.0   

Current portion of long-term debt

      36.6         37.4   

Long-term debt, net of current portion

      5,883.5         5,982.9   

Deferred income taxes, long-term

      1,370.4         1,487.6   

Other long-term liabilities

      206.8         172.0   

Shareholder's equity

      3,111.1         3,175.1   
  

 

 

     

 

 

  

Total Liabilities and Shareholder's Equity

    $ 11,138.6       $ 11,357.0   
  

 

 

     

 

 

  

Net Debt (a)*

    $ 5,424.1       $ 5,659.4   

 

(a) Net debt is the sum of total debt less cash and cash equivalents, as defined by the credit agreement. Cash and cash equivalents at May 31, 2011 includes $33.1 million of time deposits with maturities of less than 2 years.
* See Non-GAAP Financial Measures Disclosure

 

Biomet, Inc.

Other Financial Information

Reconciliation of Senior Secured Leverage Ratio and Total Leverage Ratio*

(in millions, except ratios, unaudited)

 

     February 29, 2012          May 31, 2008      

Senior Secured Debt:

          

USD Term Loan B

    $ 2,240.6         $ 2,328.3     

EUR Term Loan B

      1,125.4           1,355.2     

Asset Based Revolver

      —             —       

Cash Flow Revolvers

      —             —       
  

 

 

       

 

 

    

Consolidated Senior Secured Debt

      3,366.0      A      3,683.5      E

Senior Notes

      2,550.0           2,570.7     

European Operations

      4.1           46.6     
  

 

 

       

 

 

    

Consolidated Total Debt

      5,920.1           6,300.8     

Cash and Cash Equivalents* **

      (496.0 )    B      (127.6 )    F
  

 

 

       

 

 

    

Net Debt*

    $ 5,424.1      C    $ 6,173.2      G
  

 

 

       

 

 

    

LTM Adjusted EBITDA

          

Quarter 4 Fiscal 2011 Adjusted EBITDA

      260.9          

Quarter 1 Fiscal 2012 Adjusted EBITDA

      226.6          

Quarter 2 Fiscal 2012 Adjusted EBITDA

      266.3          
         

Quarter 3 Fiscal 2012 Adjusted EBITDA

      260.5          

“Run Rate” Cost Savings**

      —            
  

 

 

         

Quarter 3 2012 LTM Adjusted EBITDA*

    $ 1,014.3      D     
  

 

 

         

Fiscal 2008 LTM Adjusted EBITDA

           829.1     

“Run Rate” Cost Savings**

           57.0     
       

 

 

    

Fiscal 2008 LTM Adjusted EBITDA*

         $ 886.1      H
       

 

 

    

Senior Secured Leverage Ratio*

      2.83      A+B / D      4.01      E+F / H

Total Leverage Ratio*

      5.35      C / D      6.97      G / H

 

* See Non-GAAP Financial Measures Disclosure
** As defined by the Credit Agreement dated September 25, 2007

Biomet, Inc.

Other Financial Information

Reconciliation of Net Loss, as reported to EBITDA, as adjusted*

(in millions, unaudited)

 

     Three Months Ended
May 31, 2011		  

Net loss, as reported

    $ (812.8 ) 

Depreciation

      46.9   

Amortization

      84.6   

Interest expense

      125.2   

Other (income) expense

      (2.5 ) 

Income tax benefit

      (157.2 ) 

Stock-based compensation expense

      (1.9 ) 

Litigation settlements and reserves and other legal fees

      2.8   

Operational restructuring and consulting expenses related to operational initiatives (severance, building impairments, abnormal manufacturing variances and other related costs)

      31.9   

Sponsor fee

      2.5   

Goodwill and intangible assets impairment charge

      941.4   
  

 

 

  

EBITDA, as adjusted*

    $ 260.9   
  

 

 

  
     Year Ended
May 31, 2008		  

Net loss, as reported

    $ (1,018.8 ) 

Depreciation

      140.8   

Amortization

      329.8   

Interest expense

      516.6   

Other (income) expense

      9.1   

Income tax benefit

      (257.4 ) 

Additional cost of sales for inventory write up to fair value

      160.2   

In-process research and development

      479.0   

Financing fees related to merger

      171.6   

Share-based payment

      25.8   

In-the-money stock option settlement

      112.8   

Distributor agreements

      41.7   

Department of Justice

      26.9   

Investment banker fee

      29.6   

Consulting expenses related to operational improvement initiatives, severance for former executives, sponsor fees and other related costs

      49.6   

Additional legal/merger related fees

      11.8   
  

 

 

  

EBITDA, as adjusted*

    $ 829.1   
  

 

 

  

 

* See Non-GAAP Financial Measures Disclosure

Biomet, Inc.

Consolidated Statement of Cash Flows

(in millions, unaudited)

 

     Fiscal 2012  
     Three Months Ended
August 31, 2011		     Three Months Ended
November 30, 2011		     (Preliminary)
Three Months Ended
February 29, 2012		     (Preliminary)
Nine Months Ended
February 29, 2012		  

CASH FLOWS PROVIDED BY (USED IN) OPERATING ACTIVITIES:

         

Net loss

    $ (39.2 )    $ (14.0 )    $ (16.5 )    $ (69.7 ) 

Adjustments to reconcile net loss to net cash provided by operating activities:

         

Depreciation and amortization

      129.8        131.7        126.5        388.0   

Amortization of deferred financing costs

      2.8        2.7        2.8        8.3   

Stock-based compensation expense

      4.7        4.0        3.5        12.2   

Recovery of doubtful accounts receivable

      (2.5 )      —          (0.1 )      (2.6 ) 

Realized gain on investmetns

      —          —          (1.9 )      (1.9 ) 

Loss on impairment of investments

      9.2        7.3        2.8        19.3   

Property, plant and equipment impairment charge

      —          0.4        —          0.4   

Provision for inventory obsolescence

      (0.5 )      4.3        5.7        9.5   

Deferred income taxes

      (67.0 )      (20.6 )      (33.1 )      (120.7 ) 

Other

      (0.6 )      2.4        (3.8 )      (2.0 ) 

Changes in operating assets and liabilities:

         

Accounts receivable

      21.3        (59.2 )      (0.5 )      (38.4 ) 

Inventories

      (2.2 )      3.6        (1.3 )      0.1   

Prepaid expenses

      2.7        (0.7 )      (3.2 )      (1.2 ) 

Accounts payable

      (1.5 )      7.7        (10.4 )      (4.2 ) 

Income taxes

      22.4        (4.6 )      1.3        19.1   

Accrued interest

      67.8        (73.2 )      67.1        61.7   

Accrued expenses and other

      (24.1 )      18.9        18.6        13.4   
  

 

 

    

 

 

    

 

 

    

 

 

  

Net cash provided by operating activities

      123.1        10.7        157.5        291.3   

CASH FLOWS PROVIDED BY (USED IN) INVESTING ACTIVITIES:

         

Proceeds from sales/maturities of investments

      33.7        —          8.3        42.0   

Purchases of investments

      (0.2 )      —          (0.1 )      (0.3 ) 

Proceeds from sale of property and equipment

      0.1        13.0        0.6        13.7   

Capital expenditures

      (39.2 )      (42.0 )      (41.5 )      (122.7 ) 

Acquisitions, net of cash acquired

      (3.9 )      (10.5 )      —          (14.4 ) 
  

 

 

    

 

 

    

 

 

    

 

 

  

Net cash used in investing activities

      (9.5 )      (39.5 )      (32.7 )      (81.7 ) 

CASH FLOWS PROVIDED BY (USED IN) FINANCING ACTIVITIES:

         

Debt:

         

Payments under European facilties

      (0.5 )      (0.3 )      (0.3 )      (1.1 ) 

Payments under senior secured credit facilities

      (8.9 )      (9.1 )      (8.6 )      (26.6 ) 

Equity:

         

Repurchase of LVB Acquisition, Inc. shares

      (0.3 )      (0.8 )      (0.1 )      (1.2 ) 
  

 

 

    

 

 

    

 

 

    

 

 

  

Net cash used in financing activities

      (9.7 )      (10.2 )      (9.0 )      (28.9 ) 

Effect of exchange rate changes on cash

      (0.5 )      (8.3 )      (3.7 )      (12.5 ) 
  

 

 

    

 

 

    

 

 

    

 

 

  

Increase (decrease) in cash and cash equivalents

      103.4        (47.3 )      112.1        168.2   

Cash and cash equivalents, beginning of period

      327.8        431.2        383.9        327.8   
  

 

 

    

 

 

    

 

 

    

 

 

  

Cash and cash equivalents, end of period

    $ 431.2      $ 383.9      $ 496.0      $ 496.0   
  

 

 

    

 

 

    

 

 

    

 

 

  

Supplemental disclosures of cash flow information:

         

Cash paid during the period for:

         

Interest

    $ 55.0      $ 191.7      $ 47.3      $ 294.0   
  

 

 

    

 

 

    

 

 

    

 

 

  

Income taxes

    $ 20.7      $ 16.1      $ 40.1      $ 76.9   
  

 

 

    

 

 

    

 

 

    

 

 

  

Biomet, Inc.

Consolidated Statement of Cash Flows

(in millions, unaudited)

 

     Fiscal 2011  
     Three Months Ended
August 31, 2010		     Three Months Ended
November 30, 2010		     Three Months Ended
February 28, 2011		     NIne Months Ended
February 28, 2011		  

CASH FLOWS PROVIDED BY (USED IN) OPERATING ACTIVITIES:

         

Net loss

    $ (17.8 )    $ (7.6 )    $ (11.6 )    $ (37.0 ) 

Adjustments to reconcile net loss to net cash provided by operating activities:

         

Depreciation and amortization

      136.7        139.5        141.3        417.5   

Amortization of deferred financing costs

      2.8        2.9        2.7        8.4   

Stock-based compensation expense

      5.1        4.3        5.2        14.6   

Recovery of doubtful accounts receivable

      (1.3 )      (0.3 )      (2.3 )      (3.9 ) 

Gain on sale of investments

      —          (2.6 )      (2.3 )      (4.9 ) 

Provision for inventory obsolescence

      1.7        5.3        4.8        11.8   

Deferred income taxes

      (43.8 )      (10.6 )      (44.0 )      (98.4 ) 

Other

      0.5        (18.2 )      7.4        (10.3 ) 

Changes in operating assets and liabilities:

         

Accounts receivable

      27.1        (28.6 )      13.2        11.7   

Inventories

      (18.3 )      (33.2 )      (13.5 )      (65.0 ) 

Prepaid expenses

      (12.2 )      10.5        (6.7 )      (8.4 ) 

Accounts payable

      (0.6 )      3.0        (9.6 )      (7.2 ) 

Income taxes

      4.3        2.9        6.8        14.0   

Accrued interest

      67.7        (74.3 )      67.7        61.1   

Accrued expenses and other

      (20.6 )      27.1        (7.3 )      (0.8 ) 
  

 

 

    

 

 

    

 

 

    

 

 

  

Net cash provided by operating activities

      131.3        20.1        151.8        303.2   

CASH FLOWS PROVIDED BY (USED IN) INVESTING ACTIVITIES:

         

Proceeds from sales/maturities of investments

      3.8        7.9        2.9        14.6   

Purchases of investments

      —          —          (44.3 )      (44.3 ) 

Proceeds from sale of property and equipment

      —          4.8        1.3        6.1   

Capital expenditures

      (36.5 )      (52.3 )      (45.1 )      (133.9 ) 

Acquisitions, net of cash acquired

      (9.6 )      (6.8 )      (1.9 )      (18.3 ) 
  

 

 

    

 

 

    

 

 

    

 

 

  

Net cash used in investing activities

      (42.3 )      (46.4 )      (87.1 )      (175.8 ) 

CASH FLOWS PROVIDED BY (USED IN) FINANCING ACTIVITIES:

         

Debt:

         

Proceeds under European facilities

      0.1        —          0.1        0.2   

Payments under European facilities

      (0.6 )      (0.5 )      (0.4 )      (1.5 ) 

Payments under senior secured credit facilities

      (8.5 )      (8.7 )      (8.7 )      (25.9 ) 

Repurchases of senior notes

      —          (11.2 )      —          (11.2 ) 

Equity:

         

Repurchase of LVB Acquisition, Inc. shares

      (0.2 )      (0.8 )      (0.2 )      (1.2 ) 
  

 

 

    

 

 

    

 

 

    

 

 

  

Net cash used in financing activities

      (9.2 )      (21.2 )      (9.2 )      (39.6 ) 

Effect of exchange rate changes on cash

      5.1        2.1        3.6        10.8   
  

 

 

    

 

 

    

 

 

    

 

 

  

Increase (decrease) in cash and cash equivalents

      84.9        (45.4 )      59.1        98.6   

Cash and cash equivalents, beginning of period

      189.1        274.0        228.6        189.1   
  

 

 

    

 

 

    

 

 

    

 

 

  

Cash and cash equivalents, end of period

    $ 274.0      $ 228.6      $ 287.7      $ 287.7   
  

 

 

    

 

 

    

 

 

    

 

 

  

Supplemental disclosures of cash flow information:

         

Cash paid during the period for:

         

Interest

    $ 56.3      $ 194.5      $ 53.6      $ 304.4   
  

 

 

    

 

 

    

 

 

    

 

 

  

Income taxes

    $ 6.5      $ 11.2      $ 10.5      $ 28.2   
  

 

 

    

 

 

    

 

 

    

 

 

  

Biomet, Inc.

Other Financial Information

GAAP Operating Cash Flow Reconciled to Free Cash Flow* & Unlevered Free Cash Flow*

(in millions, unaudited)

 

    Fiscal 2012  
    Three Months Ended
August 31, 2011		     Three Months Ended
November 30, 2011		     (Preliminary)
Three Months Ended
February 29, 2012		     (Preliminary)
Nine Months Ended
February 29, 2012		  

Net loss

   $ (39.2 )    $ (14.0 )    $ (16.5 )    $ (69.7 ) 

Adjustments:

        

Depreciation and amortization

     129.8        131.7        126.5        388.0   

Amortization of deferred financing costs

     2.8        2.7        2.8        8.3   

Stock-based compensation expense

     4.7        4.0        3.5        12.2   

Recovery of doubtful accounts receivable

     (2.5 )      —          (0.1 )      (2.6 ) 

Realized gain on investmetns

     —          —          (1.9 )      (1.9 ) 

Loss on impairment of investments

     9.2        7.3        2.8        19.3   

Property, plant and equipment impairment charge

     —          0.4          0.4   

Provision for inventory obsolescence

     (0.5 )      4.3        5.7        9.5   

Deferred income taxes

     (67.0 )      (20.6 )      (33.1 )      (120.7 ) 

Other

     (0.6 )      2.4        (3.8 )      (2.0 ) 
 

 

 

    

 

 

    

 

 

    

 

 

  

TOTAL

     36.7        118.2        85.9        240.8   

Changes In:

        

Accounts receivable

     21.3        (59.2 )      (0.5 )      (38.4 ) 

Inventories

     (2.2 )      3.6        (1.3 )      0.1   

Prepaid expenses

     2.7        (0.7 )      (3.2 )      (1.2 ) 

Accounts payable

     (1.5 )      7.7        (10.4 )      (4.2 ) 

Income taxes

     22.4        (4.6 )      1.3        19.1   

Accrued interest

     67.8        (73.2 )      67.1        61.7   

Accrued expenses and other

     (24.1 )      18.9        18.6        13.4   
 

 

 

    

 

 

    

 

 

    

 

 

  

Net cash provided by operating activities

   $ 123.1      $ 10.7      $ 157.5      $ 291.3   

Capital expenditures

     (39.2 )      (42.0 )      (41.5 )      (122.7 ) 
 

 

 

    

 

 

    

 

 

    

 

 

  

Free Cash Flow*

   $ 83.9      $ (31.3 )    $ 116.0      $ 168.6   

Acquisitions, net of cash acquired

     (3.9 )      (10.5 )      —          (14.4 ) 

Proceeds from sales/maturities of investments

     33.7        —          8.3        42.0   

Purchases of investments

     (0.2 )      —          (0.1 )      (0.3 ) 

Proceeds from sale of property and equipment

     0.1        13.0        0.6        13.7   

Repurchase of LVB Acquisition, Inc. shares

     (0.3 )      (0.8 )      (0.1 )      (1.2 ) 

Add back: cash paid for interest

     55.0        191.7        47.3        294.0   

Effect of exchange rates on cash

     (0.5 )      (8.3 )      (3.7 )      (12.5 ) 
 

 

 

    

 

 

    

 

 

    

 

 

  

Unlevered Free Cash Flow* (1)

   $ 167.8      $ 153.8      $ 168.3      $ 489.9   
 

 

 

    

 

 

    

 

 

    

 

 

  

 

(1) Cash flow that does not take into account the interest payments required on outstanding debt, among other financing and investing activities. Commonly used by companies that are highly leveraged to show how assets perform before debt service (principal and interest).
* See Non-GAAP Financial Measures Disclosure

Biomet, Inc.

Other Financial Information

GAAP Operating Cash Flow Reconciled to Free Cash Flow* & Unlevered Free Cash Flow*

(in millions, unaudited)

 

     Fiscal 2011  
     Three Months Ended     Three Months Ended     Three Months Ended     Nine Months Ended  
     August 31, 2010     November 30, 2010     February 28, 2011     February 28, 2011  

Net loss

    $ (17.8 )    $ (7.6 )    $ (11.6 )    $ (37.0 ) 

Adjustments:

         

Depreciation and amortization

      136.7        139.5        141.3        417.5   

Amortization of deferred financing costs

      2.8        2.9        2.7        8.4   

Stock-based compensation expense

      5.1        4.3        5.2        14.6   

Recovery of doubtful accounts receivable

      (1.3 )      (0.3 )      (2.3 )      (3.9 ) 

Gain on sale of investments

      —          (2.6 )      (2.3 )      (4.9 ) 

Provision for inventory obsolescence

      1.7        5.3        4.8        11.8   

Deferred income taxes

      (43.8 )      (10.6 )      (44.0 )      (98.4 ) 

Other

      0.5        (18.2 )      7.4        (10.3 ) 
  

 

 

    

 

 

    

 

 

    

 

 

  

TOTAL

      83.9        112.7        101.2        297.8   

Changes In:

         

Accounts receivable

      27.1        (28.6 )      13.2        11.7   

Inventories

      (18.3 )      (33.2 )      (13.5 )      (65.0 ) 

Prepaid expenses

      (12.2 )      10.5        (6.7 )      (8.4 ) 

Accounts payable

      (0.6 )      3.0        (9.6 )      (7.2 ) 

Income taxes

      4.3        2.9        6.8        14.0   

Accrued interest

      67.7        (74.3 )      67.7        61.1   

Accrued expenses and other

      (20.6 )      27.1        (7.3 )     
 (0.8
 ) 
  

 

 

    

 

 

    

 

 

    

 

 

  

Net cash provided by operating activities

    $ 131.3      $ 20.1      $ 151.8      $ 303.2   

Capital expenditures

      (36.5 )      (52.3 )      (45.1 )      (133.9 ) 
  

 

 

    

 

 

    

 

 

    

 

 

  

Free Cash Flow*

    $ 94.8      $ (32.2 )    $ 106.7      $ 169.3   

Acquisitions, net of cash acquired

      (9.6 )      (6.8 )      (1.9 )      (18.3 ) 

Proceeds from sales/maturities of investments

      3.8        7.9        2.9        14.6   

Purchases of investments

      —          —          (44.3 )      (44.3 ) 

Proceeds from sale of property and equipment

      —          4.8        1.3        6.1   

Loss on bond repurchase

      —          (1.2 )      —          (1.2 ) 

Repurchase of LVB Acquisition, Inc. shares

      (0.2 )      (0.8 )      (0.2 )      (1.2 ) 

Add back: cash paid for interest

      56.3        194.5        53.6        304.4   

Effect of exchange rates on cash

      5.1        2.1        3.6        10.8   
  

 

 

    

 

 

    

 

 

    

 

 

  

Unlevered Free Cash Flow* (1)

    $ 150.2      $ 168.3      $ 121.7      $ 440.2   
  

 

 

    

 

 

    

 

 

    

 

 

  

 

(1) Cash flow that does not take into account the interest payments required on outstanding debt, among other financing and investing activities. Commonly used by companies that are highly leveraged to show how assets perform before debt service (principal and interest).
* See Non-GAAP Financial Measures Disclosure